CF-301, produced by fermentation at concentrations exceeding 5g/l, is soluble, stable and potent.
The Lysins possess a therapeutic window that occurs virtually instantly while the Monoclonal Antibodies remain in the blood stream for weeks and provide long-term benefit.
ContraFect chairman and CEO Robert Nowinski said with the addition of this latest Lysin, their second against Staphylococcus, ContraFect has added depth to its clinical program and pipeline.
ContraFect Business Development VP Barry Kappel said CF-301 moves directly to the front of their pipeline and they anticipate having an IND-submission to the FDA for this product in Q2 2012.
"Its potent activity against all forms of Staph infections, including methicillin-resistant (MRSA) and vancomycin-resistant strains (VISA/VRSA), makes this molecule of extreme importance, not only to ContraFect, but world-wide as well," Kappel said.